ÐÇ¿ÕÊÓÆµ Health Data Use Case Study Library
To help understand why ÐÇ¿ÕÊÓÆµ data is crucial for research, developing innovative, safe, and effective medicines, we have created a publicly accessible case study library.
This new ÐÇ¿ÕÊÓÆµ health data case study library contains examples of how the pharmaceutical industry has used ÐÇ¿ÕÊÓÆµ data in medical research and the benefits that have emerged as a result. These examples cover different therapeutic areas, datasets and types of research.
Why the pharmaceutical industry needs ÐÇ¿ÕÊÓÆµ data to develop new medicinesÌý
To accompany the launch of the Industry Use of Health Data Case Study Library, ÐÇ¿ÕÊÓÆµ Executive Director for Research and Innovation, Janet Valentine, explains Ìýwhy it is important for the pharmaceutical industry to access to anonymised ÐÇ¿ÕÊÓÆµ data for research to develop new safe and Ìýeffective medicines that benefit patients in the UK and globally.
Ìý
Hip fractures relating to weak and brittle bones are a global public health concern, with over 10 million cases per year globally.
Gaucher disease is a rare genetic condition where fatty substances build up in organs, like the liver, spleen and bones.
Many causes of disease are associated with an individual’s genetic make-up and there is increasing interest in medical research to understand how our genes might influence our chances of getting a disease.
Kidney cancer is the 6th most common cancer in the UK, with over 10,000 new cases per year.
This study, carried out by Pfizer, used data from Hospital Episode Statistics data and the SACT registry dataset to explore the impact of invasive fungal infections (IFIs) in patients living with cancer.
More than one billion medicines are prescribed each year in the UK, but a large proportion of patients do not take their medication as instructed, which can lead to worse health outcomes.
Cardiovascular disease (CVD) is a leading cause of death and illness among individuals with type 2 diabetes (T2D).